• Development of original patented drugs with high therapeutic potential in collaboration with academic research centres and biotech companies.

  • From lab to
          proof of concept

About us
We select promising innovative/patented molecules with high therapeutic potential. We design and execute the complete development programme, from the laboratory to the manufacturing scale, including pre-clinical and clinical (phase I, IIA, IIB) studies, proof of concept, formulation and industrial development.
Alaxia is a French private biotech company subsidiary of Stragen developing therapeutic solutions for respiratory diseases based on its proprietary peroxidase platform. The most advanced drug candidate, ALX‑009, is an antimicrobial innovative compound aiming at treating cystic fibrosis, including the most resistant bacterial strains.

STRAGEN/ALAXIA is developing a first in class orphan drug candidate for Cystic Fibrosis adressing a strong unmet medical need
Lyon, France, June 30th, 2016. Alaxia SAS announced today an agreement with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), Bethesda, Md., to help support the first-in-patient clinical study of its inhaled antimicrobial drug candidate ALX‑009.

By delivering two key endogenous antimicrobial substances directly to the lung, ALX‑009 is intended to compensate for the defective innate lung defense system of people with cystic fibrosis (CF). ALX‑009 already demonstrated in vitro its therapeutic potential against a wide range of bacterial species infecting CF lungs and particularly against clinical isolates with natural or acquired multi-drug resistance. ALX‑009 efficacy is not altered by complex structures such as biofilm or sputum present in CF lungs. ALX‑009 has the potential to limit emergence of resistance and induction of cross-resistance to available antibiotics thanks to its innovative mode of action. A Phase I clinical trial involving healthy volunteers and CF patients is ongoing.

CFFT, the nonprofit drug discovery and development arm of the Cystic Fibrosis Foundation, committed $1.7 million to Alaxia to expedite the development of ALX‑009 for cystic fibrosis patients.

Pascale Gaillard, General Manager of Alaxia, commented on the award: “We are honored and delighted that Cystic Fibrosis Foundation Therapeutics recognizes the unique therapeutic potential of our drug candidate by supporting the development of ALX‑009. This CFFT award enables us to accelerate the clinical development of ALX‑009, and we really appreciate working with CFFT on the remaining clinical development path in bringing this new drug to people with cystic fibrosis.”

About Cystic Fibrosis:
Cystic fibrosis (CF) is a life-threatening disease that affects the lungs and digestive system and impacts about 70,000 people worldwide. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in either no CFTR protein or an abnormal CFTR protein that does not function properly. This dysfunctional protein causes the body to accumulate excessive levels of unusually thick mucus in the lungs. This excessive sticky mucus becomes a site for recurrent infections that can require hospitalization. Respiratory distress in CF — defined as acute difficulty in breathing, infection and/or hospitalization — is most commonly related to mucus accumulation and lung infections that result in damage to lung tissue.

For more information on CF, please visit www.cff.org.

About Alaxia SAS:
Alaxia SAS is a French clinical stage biotech company affiliated to Stragen Pharma and supported by BPI France. For additional info, please, visit www.alaxia-pharma.eu.

Alaxia’s aim is to address unmet medical needs, fighting infections through its innovative Hypothiocyanite/Lactoferrin technology, by developing products and therapies to market or license to suitable partners.

A pdf of this press release can be found here: Alaxia CFFT Award Press Release
STRAGEN/ALAXIA is developing a first in class orphan drug candidate for Cystic Fibrosis adressing a strong unmet medical need
Logo Alaxia
Logo Stragen
ALX‑009, a first in class orphan drug candidate for Cystic Fibrosis (CF)
  • Innovative approach: association of two endogenous substances contributing to the innate immune system response
  • Strong and broad antimicrobial activity: targets multi-drug resistant (MDR) bacterial infections not treatable by current antibiotic therapies
  • Innovative mode of action: a real added-value over existing antibiotics:
    - Activity unaffected by CF patients sputum.
    - No emergence of bacterial resistance
  • FIM clinical trial including CF patients in progress
    Completion: June 2017
  • PoC in CF (MDR infections in adults) to start mid 2018
ALX‑009, a symptomatic treatment complementary to disease modifying therapies
  • Ready-to-inhale solution for the treatment of lung infections
  • Addresses a strong unmet medical need.
    CF ‘MDR population’: 10 000 / 70 000 patients WW
  • Adjunct to existing therapies. Disease modifying therapies (Kalydeco®/Orkambi®) do not demonstrate efficacy on lung infections
ALX‑009 gathers the key attributes of an attractive novel therapy for CF
Therapeutic Potential of Inhaled ALX‑009 (OSCN-/ bLF) for the treatment of Achromobacter spp. infections in Cystic Fibrosis
C. Bechetoille, Y. Sonmez, L. Jubeau and V. Juarez-Perez
ECFS Basel, Switzerland , 39th annual congress , June 8-11, 2016
Therapeutic potential of inhaled ALX‑009 (OSCN-/bLF) for emergent and multiresistant bacteria infections in Cystic Fibrosis,
Y. Sonmez, C. Bechetoille, S. Perrotto and V. Juarez-Perez
ENACFC Phoenix, Arizona , 29th annual congress , Oct 8-10, 2015
Successful Burkholderia spp. eradication with hypothiocyanite/lactoferrin. In vitro study evidence over a worldwide collection of clinical strains,
Y. Sonmez, C. Bechetoille, S. Perrotto, A. Payet-Burin, V. Juarez-Perez
ECFS Brussels, Belgium, 38th annual congress , June 10-13, 2015
Burkholderia spp. Resistances strategies. OSCN-/bLF (ALX‑009), Is its mode of action a bulwark against bacterial resistance?
Victor Juarez-Perez, Camille Bechetoille, Yasmine Somnez and Sandrine Perrotto
IBCWP Vancouver, Canada. 19th annual congress. April 15-18, 2015
Bactericidal potential of OSCN-, bovine lactoferrin and their combination on clinical isolates of Burkholderia spp,
Y. Sonmez, C. Bechetoille, S. Perrotto, A. Payet-Burin, V. Juarez-Perez
NACFC Atlanta, Georgia, 28th annual congress , Oct 9-11, 2014
Bactericidal potential of OSCN-, bovine Lactoferrin and their combination over clinical strains of Burkholderia spp.
Yasmine Sonmez, Camille Bechetoille, Sandrine Perrotto, Alban Payet-Burin, Paul Claudon and Victor Juarez-Perez
IBCWP Nimes, France, 18th annual congress. April 8-12, 2014
ALX-109 potentiates the effect of inhaled antibiotics at killing Pseudomonas aeruginosa biofilms on human airway cells,
S. Moreau-Marquis, J.D. Drexinger, V. Juarez Perez, B.A. Stanton
NACFC Orlando, Florida, 26th annual congress , Oct 11-13, 2012 ECFS Lisbon, Portugal, 36th annual congress , June 12-15, 2013
Feasibility study of OSCN− and lactoferrin (Meveol®) nebulization for Cystic Fibrosis patients,
S. Perrotto, S. Le Guellec, L. Vecellio, E. Fichant, P. Stordeur, P. Bordeau, J.P Perraudin
ECFS Hamburg, Germany, 34th annual congress , June 8-11, 2011
Exclusive License from Institut Pasteur Paris, France
The innovative mode of action of STR-324 provides a safe, non-addictive treatment for Neuropathic pain conditions
STR-324: a first-in-class non opioid painkiller with a safe, non-addictive innovative mode of action
  • Synthetic equivalent of a natural occurring human pentapeptide
  • Inhibits the degradation of enkephalins, endogenous painkillers released only during and at the site of a painful situation
  • Efficacy on acute and prolonged pain, including neuropathic pain animal models with non-addictive behavior
  • In contrast to opioids, absence of respiratory, gastro-intestinal or central nervous system side effects in animals
  • 2016: Complete preclinical and galenic development
  • 2017 - 2018: First in Man trial with an injectable form
  • 2019: PoC on Neuropathic pain
*Grace et al. 2016. PNAS doi: 10.1073/pnas.1602070113
STR-324: a first-in-class non opioid pain treatment to treat Neuropathic pain (NP)
  • STR-324 first indication will address NP treatment
  • The market for drugs used in NP is booming and is expected to reach $5.2 billions by 2018
  • 7–8% of adults currently have NP. According to a UK study, 7% of people with NP had health-related quality of life scores equivalent to “worse than death”
  • NP is chronic, severe and resistant to most current medications: pain relief is achieved only for 40-60% of patients but with considerable side effects
  • Due to the intrinsic cause of NP, opioids are not only inefficient in treating this condition, but new data suggest that these drugs may prolong NP* states
  • By its unique mode of action, STR-324 will preserve the physiological capacity of the human body to control pain at the right time at the right place without undesirable side-effects
The innovative mode of action of STR-324 provides a safe, non-addictive treatment for Neuropathic pain conditions
Omacetaxine: a potent inducer of apoptosis (programmed cell death) in myeloid cells and inhibitor of angiogenesis (blood vessel formation).
  • 2004 - Start of development programme
  • 2005 - License to Chemgenex
  • 2008 - Stragen becomes shareholder of Chemgenex
  • 2011 - Cephalon purchases Chemgenex for USD 230 million
  • 2012 (October) - FDA approval